Myovant and Pfizer showed that deal-making was not taking a Christmas break, but for Celgene CVR holders the dream is almost over. And vaccine approvals gained pace.
It is vital that the first authorised at-home, non-prescription Covid-19 antigen test be used in the right way.
A new UK plan to use antigen tests for wide-scale screening for Covid-19 may not be the easy win the government is seeking.
The $13.1bn price suggests that Bristol could be banking on mavacamten’s potential outside rare diseases.
LY-CoV555 shows promising signs for the antibody approach, with Regeneron not far behind.
Positive phase III data in hand, Myokardia heads to the FDA.
Global drug stocks enthusiastically joined the recovery on the financial markets in the second quarter, more than offsetting earlier declines.